Impact of Abcc2 [multidrug resistance-associated protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate

Drug Metabolism and Disposition

Volumn 39, Issue 8, 2011, Pages 1338-1344

  Vlaming, Maria L H ^a,c   Van Esch, Anita ^a   Van De Steeg, Evita ^a,c   Pala, Zeliha ^b   Wagenaar, Els ^a   Van Tellingen, Olaf ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ISTANBUL UNIVERSITY   (Turkey)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; BREAST CANCER RESISTANCE PROTEIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRAIN DIFFERENCE; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; FEMALE; INJECTIONS, INTRAVENOUS; METHOTREXATE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGAN SPECIFICITY; TISSUE DISTRIBUTION;

MUS;

EID: 79960566731     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038794     Document Type: Article

References (28)

1. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, and van Tellingen O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421.
2. Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592. (Pubitemid 34800230)
3. Borst P, Zelcer N, and van de Wetering K (2006) MRP2 and 3 in health and disease. Cancer Lett 234:51-61. (Pubitemid 43343940)
4. Breedveld P, Beijnen JH, and Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24. (Pubitemid 43063120)
5. Bremnes RM, Slørdal L, Wist E, and Aarbakke J (1989) Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration. Cancer Res 49:2460-2464. (Pubitemid 19125579)
6. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, and Liu X (2003) Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res 20:31-37. (Pubitemid 36152914)
7. Chládek J, Martínková J, and Sispera L (1997) An in vitro study on methotrexate hydroxylation in rat and human liver. Physiol Res 46:371-379. (Pubitemid 27471204)
8. Gorlick R and Bertino JR (1999) Clinical pharmacology and resistance to dihydrofolate reductase inhibitors, in Antifolate Drugs in Cancer Therapy (Jackman AN ed) pp 37-57, Humana Press, Totowa, NJ.
9. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
10. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654. (Pubitemid 35403986)
11. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, and Sugiyama Y (2008) Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3). J Pharmacol Exp Ther 327:465-473.
12. Kruh GD, Belinsky MG, Gallo JM, and Lee K (2007) Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev 26:5-14.
13. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002a) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950.
14. Kruijtzer CM, Beijnen JH, and Schellens JH (2002b) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516-530. (Pubitemid 36009000)
15. Kuppens IE, Breedveld P, Beijnen JH, and Schellens JH (2005) Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 23:443-464. (Pubitemid 41324362)
16. Murakami T and Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
17. Naba H, Kuwayama C, Kakinuma C, Ohnishi S, and Ogihara T (2004) Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions. Drug Metab Pharmacokinet 19:339-351.
18. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, and McLeod HL (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572-579. (Pubitemid 351500051)
19. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29. (Pubitemid 36078452)
20. van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, and Borst P (2007) Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 72:387-394. (Pubitemid 47124119)
21. van Herwaarden AE and Schinkel AH (2006) The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27:10-16.
22. van Tellingen O, van der Woude HR, Beijnen JH, van Beers CJ, and Nooyen WJ (1989) Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids. J Chromatogr 488:379-388. (Pubitemid 19122094)
23. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, et al. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
24. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, and Schinkel AH (2009a) Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15:3084-3093.
25. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, and Schinkel AH (2008) Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 14:8152-8160.
26. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, and Schinkel AH (2009b) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350-3359.
27. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, and Griffiths CE (2008) Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925-1929. (Pubitemid 352001201)
28. Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, et al. (2006) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44:768-775.